written on 24.01.2014

More biosimilar approvals for Celltrion as it closes in on the US market


Two major biosimilar product approvals for Celltrion, in South Korea and Canada, will serve to consolidate the South Korean firm's already strong competitive position in the biosimilar MAb space as it moves towards a filing in the key US market.